Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by WalkOverTheStrton Aug 13, 2021 5:22pm
220 Views
Post# 33704854

A PH2 recommendation

A PH2 recommendationAdvice to mgmt: Run the trial with 50mg and 75mg through four weeks, not two like the previous PH2.
Why?....

1) WOMAC scores - Allows more time for HS2 to work - Joe during the Canaccord meeting at minute 10:30 points out that Otnenal WOMAC scores which are inline with other NSAIDS studies but Otenal was at two weeks vs the others at 12 weeks...Alluding to fact pain reduction could / likely would increase over time making the case for 75mg. Heck also test 50mg... 
If this isnt being considered by Joe than someone close to him nudge him...

2) Better to fail in a PH2 and highlight a safety issue on a longer term dose than have even more sunk costs for a PH3. If liver and other functions are good at 75mg and / or 50mg AND WOMAC meets the bar then they know PH3 should also be fine. 


Slide 16 - https://secureservercdn.net/72.167.241.46/ln9.cea.myftpupload.com/wp-content/uploads/2021/07/Antibe-Corporate-Presentation-July-2021.pdf
<< Previous
Bullboard Posts
Next >>